{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:28:13Z","timestamp":1761895693261},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2013,5,20]],"date-time":"2013-05-20T00:00:00Z","timestamp":1369008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,5,20]],"date-time":"2013-05-20T00:00:00Z","timestamp":1369008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1038\/bmt.2013.71","type":"journal-article","created":{"date-parts":[[2013,5,20]],"date-time":"2013-05-20T11:02:09Z","timestamp":1369047729000},"page":"1450-1455","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Duration of first remission, hematopoietic cell transplantation-specific comorbidity index and patient age predict survival of patients with AML transplanted in second CR"],"prefix":"10.1038","volume":"48","author":[{"given":"F V","family":"Michelis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E G","family":"Atenafu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D D","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Kuruvilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Lambie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J H","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Loach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H A","family":"Messner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,5,20]]},"reference":[{"key":"BFbmt201371_CR1","first-page":"114","volume":"24","author":"FR Appelbaum","year":"1997","unstructured":"Appelbaum FR . Allogeneic hematopoietic stem cell transplantation for acute leukemia. Semin Oncol 1997; 24: 114\u2013123.","journal-title":"Semin Oncol"},{"key":"BFbmt201371_CR2","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1182\/blood-2006-06-025627","volume":"109","author":"JJ Cornelissen","year":"2007","unstructured":"Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM et al. Results of a HOVON\/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 2007; 109: 3658\u20133666.","journal-title":"Blood"},{"key":"BFbmt201371_CR3","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1001\/jama.2009.813","volume":"301","author":"J Koreth","year":"2009","unstructured":"Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009; 301: 2349\u20132361.","journal-title":"JAMA"},{"key":"BFbmt201371_CR4","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1053\/bbmt.2002.v8.pm12234169","volume":"8","author":"Y Chalandon","year":"2002","unstructured":"Chalandon Y, Barnett MJ, Horsman DE, Conneally EA, Nantel SH, Nevill TJ et al. Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant 2002; 8: 435\u2013443.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201371_CR5","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","volume":"363","author":"TA Gooley","year":"2010","unstructured":"Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363: 2091\u20132101.","journal-title":"N Engl J Med"},{"key":"BFbmt201371_CR6","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1200\/JCO.2009.27.1460","volume":"28","author":"B Gyurkocza","year":"2010","unstructured":"Gyurkocza B, Storb R, Storer BE, Chauncey TR, Lange T, Shizuru JA et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol 2010; 28: 2859\u20132867.","journal-title":"J Clin Oncol"},{"key":"BFbmt201371_CR7","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912\u20132919.","journal-title":"Blood"},{"key":"BFbmt201371_CR8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1600-0609.2011.01580.x","volume":"86","author":"PG Hemmati","year":"2011","unstructured":"Hemmati PG, Terwey TH, le Coutre P, Vuong LG, Massenkeil G, D\u00f6rken B et al. A modified EBMT risk score predicts the outcome of patients with acute myeloid leukemia receiving allogeneic stem cell transplants. Eur J Haematol 2011; 86: 305\u2013316.","journal-title":"Eur J Haematol"},{"key":"BFbmt201371_CR9","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/sj.bmt.1702690","volume":"26","author":"M Michallet","year":"2000","unstructured":"Michallet M, Thomas X, Vernant JP, Kuentz M, Soci\u00e9 G, Esp\u00e9rou-Bourdeau H et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM). Bone Marrow Transplant 2000; 26: 1157\u20131163.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201371_CR10","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1200\/JCO.2005.06.027","volume":"23","author":"DA Breems","year":"2005","unstructured":"Breems DA, Van Putten WL, Huijgens PC, Ossenkoppele GJ, Verhoef GE, Verdonck LF et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005; 23: 1969\u20131978.","journal-title":"J Clin Oncol"},{"key":"BFbmt201371_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.bbmt.2004.10.008","volume":"11","author":"R Wong","year":"2005","unstructured":"Wong R, Shahjahan M, Wang X, Thall PF, De Lima M, Khouri I et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 2005; 11: 108\u2013114.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201371_CR12","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.bbmt.2009.07.008","volume":"15","author":"PM Armistead","year":"2009","unstructured":"Armistead PM, de Lima M, Pierce S, Qiao W, Wang X, Thall PF et al. Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia. Biol Blood Marrow Transplant 2009; 15: 1431\u20131438.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201371_CR13","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/bmt.2010.145","volume":"46","author":"J Krauter","year":"2011","unstructured":"Krauter J, Wagner K, Stadler M, Dammann E, Zucknick M, Eder M et al. Prognostic factors in allo-SCT of elderly patients with AML. Bone Marrow Transplant 2011; 46: 545\u2013551.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201371_CR14","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","volume":"96","author":"ML Slovak","year":"2000","unstructured":"Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group\/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075\u20134083.","journal-title":"Blood"},{"key":"BFbmt201371_CR15","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825\u2013828.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201371_CR16","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945\u2013956.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201371_CR17","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/sim.4780120803","volume":"12","author":"MS Pepe","year":"1993","unstructured":"Pepe MS, Mori M . Kaplan-meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 1993; 12: 737\u2013751.","journal-title":"Stat Med"},{"key":"BFbmt201371_CR18","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ . A proportional hazards model for the subdistribution of a competing risk. J Am Statist Assoc 1999; 94: 496\u2013509.","journal-title":"J Am Statist Assoc"},{"key":"BFbmt201371_CR19","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V88.2.756.bloodjournal882756","volume":"88","author":"E Estey","year":"1996","unstructured":"Estey E, Kornblau S, Pierce S, Kantarjian H, Beran M, Keating M . A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood 1996; 88: 756.","journal-title":"Blood"},{"key":"BFbmt201371_CR20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1046\/j.1365-2141.1999.01713.x","volume":"107","author":"AP Grigg","year":"1999","unstructured":"Grigg AP, Szer J, Beresford J, Dodds A, Bradstock K, Durrant S et al. Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia. Br J Haematol 1999; 107: 409\u2013418.","journal-title":"Br J Haematol"},{"key":"BFbmt201371_CR21","first-page":"979","volume":"17","author":"F Tom\u00e1s","year":"1996","unstructured":"Tom\u00e1s F, G\u00f3mez-Garc\u00eda de Soria V, L\u00f3pez-Lorenzo JL, Arranz R, Figuera A, C\u00e1mara R et al. Autologous or allogeneic bone marrow transplantation for acute myeloblastic leukemia in second complete remission. Importance of duration of first complete remission in final outcome. Bone Marrow Transplant 1996; 17: 979\u2013984.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201371_CR22","first-page":"998","volume":"89","author":"F Ferrara","year":"2004","unstructured":"Ferrara F, Palmieri S, Mele G . Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia. Haematologica 2004; 89: 998\u20131008.","journal-title":"Haematologica"},{"key":"BFbmt201371_CR23","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.bbmt.2011.07.024","volume":"18","author":"P Armand","year":"2012","unstructured":"Armand P, Kim HT, Zhang MJ, Perez WS, Dal Cin PS, Klumpp TR et al. Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. Biol Blood Marrow Transplant 2012; 18: 280\u2013288.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201371_CR24","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.bbmt.2003.08.004","volume":"9","author":"HC Fung","year":"2003","unstructured":"Fung HC, Stein A, Slovak M, O'donnell MR, Snyder DS, Cohen S et al. A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. Biol Blood Marrow Transplant 2003; 9: 766\u2013771.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201371_CR25","first-page":"2931","volume":"90","author":"A Ferrant","year":"1997","unstructured":"Ferrant A, Labopin M, Frassoni F, Prentice HG, Cahn JY, Blaise D et al. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood 1997; 90: 2931\u20132938.","journal-title":"Blood"},{"key":"BFbmt201371_CR26","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1200\/JCO.2006.09.7865","volume":"25","author":"ML Sorror","year":"2007","unstructured":"Sorror ML, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007; 25: 4246\u20134254.","journal-title":"J Clin Oncol"},{"key":"BFbmt201371_CR27","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.leukres.2011.11.021","volume":"36","author":"A Savic","year":"2012","unstructured":"Savic A, Kvrgic V, Rajic N, Urosevic I, Kovacevic D, Percic I et al. The hematopoietic cell transplantation comorbidity index is a predictor of early death and survival in adult acute myeloid leukemia patients. Leuk Res 2012; 36: 479\u2013482.","journal-title":"Leuk Res"},{"key":"BFbmt201371_CR28","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1016\/j.bbmt.2011.06.009","volume":"17","author":"N Birninger","year":"2011","unstructured":"Birninger N, Bornh\u00e4user M, Schaich M, Ehninger G, Schetelig J . The hematopoietic cell transplantation-specific comorbidity index fails to predict outcomes in high-risk AML patients undergoing allogeneic transplantation\u2014investigation of potential limitations of the index. Biol Blood Marrow Transplant 2011; 17: 1822\u20131832.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201371_CR29","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1200\/JCO.2007.11.1641","volume":"26","author":"D Valc\u00e1rcel","year":"2008","unstructured":"Valc\u00e1rcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008; 26: 577\u2013584.","journal-title":"J Clin Oncol"},{"key":"BFbmt201371_CR30","doi-asserted-by":"publisher","first-page":"9387","DOI":"10.1200\/JCO.2005.02.0057","volume":"23","author":"S Tauro","year":"2005","unstructured":"Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005; 23: 9387\u20139393.","journal-title":"J Clin Oncol"},{"key":"BFbmt201371_CR31","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1038\/sj.leu.2403967","volume":"19","author":"M Aoudjhane","year":"2005","unstructured":"Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19: 2304\u20132312.","journal-title":"Leukemia"},{"key":"BFbmt201371_CR32","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1182\/blood-2004-05-1947","volume":"105","author":"EP Alyea","year":"2005","unstructured":"Alyea EP, Kim HT, Ho V, Cutler C, Gribben J, DeAngelo DJ et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005; 105: 1810\u20131814.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt201371.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201371","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201371.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T17:21:25Z","timestamp":1648056085000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt201371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,20]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["BFbmt201371"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2013.71","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,20]]},"assertion":[{"value":"15 February 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We would like to disclose the financial support by Otsuka America Pharmaceuticals, Inc. for data collection and analysis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}